Transcatheter Aortic Valve Replacement (TAVR) is a minimally invasive procedure for high-risk patients with aortic stenosis that involves a high risk of developing cardiac arrhythmias and requires monitoring for 5-10 days post-surgery. Currently this monitoring is done using scares and expensive hospital telemetry beds.

A new mobile telemetry service (m-CARDS) will allow early discharge at 24 hours post-surgery, reducing pressure on hospital resources and improving patient experience.

Patients will receive pre- and post-TAVR monitoring via m-CARDS to examine the impact to cost-effectiveness, hospital readmissions, likelihood of hospital acquired infections and quality of life for patient and family.

Continuous home monitoring using the m-health solution is intended to detect intermittent conduction abnormalities, such as heart block and atrial fibrillation.

The primary objective of the Redirect TAVI study is to assess feasibility and patient and clinical team experience and to gather information useful for implementing a larger study for clinical outcomes including: length of stay post-TAVR; arrhythmia-related rehospitalizations; and cost-effectiveness.

Study Type


Study Design

Prospective cohort

NO. of Countries


NO. of Sites


NO. of Participants


Study Period




Ontario Centres for Excellence, Health Technology Fund

PHRI Digital Health Grant

M-Health Solutions

Back To Top